Literature DB >> 35813785

Ex Utero Intrapartum Treatment (EXIT) Into the World: A Multidisciplinary Approach and Outcomes in a Malaysia Tertiary Centre.

Amy Oon1, Shifa Zulkifli2, Yuen Kok Foong2, Ameen S Azhar2, Muhamad Hazim Abdul Ghafar2, Mun Yee Soo2.   

Abstract

Fetal airway obstruction that present during birth are challenging to manage. Cervical and thoracic mass may cause significant airway compression that leads to irreversible fetal morbidity and mortality. With the current advancement in prenatal diagnosis and assessment for surgical planning, EXIT has become an accepted, recognized and preferred option for safe delivery in complex head and neck masses. Ex utero intrapartum treatment (EXIT) is a life-saving procedure that provides time to establish an airway while maintaining uteroplacental circulation. It requires flawless coordination amongst multidisciplinary team to ensure immediate and safe baby deliveries. Retrospective review of EXIT procedures performed from the initial establishment of pediatric otolaryngology service in this centre starting from January 2019 to December 2020. Based on the prenatal diagnosis, five EXIT cases were performed in this centre within 2 years. 4 cases were diagnosed as lymphatic malformation and 1 immature teratoma with cervical and thoracic compression. 4 babies successfully delivered to airway without any complications with 1 death resulting from disseminated intravascular coagulopathy after EXIT. This review of five EXIT procedures aims to bring forth the different outcomes, preoperative planning and sharing our experience as a tertiary and newly established centre. Early prenatal diagnosis, good collaboration and experience among multidisciplinary team ensures good long term outcomes. © Association of Otolaryngologists of India 2021.

Entities:  

Keywords:  Ex utero intrapartum treatment; Lymphatic malformation; Paediatric tracheostomy; Teratoma

Year:  2021        PMID: 35813785      PMCID: PMC9256866          DOI: 10.1007/s12070-021-02851-y

Source DB:  PubMed          Journal:  Indian J Otolaryngol Head Neck Surg        ISSN: 2231-3796


  8 in total

Review 1.  A review of the EXIT (Ex utero Intrapartum Treatment) procedure.

Authors:  R J Abraham; A Sau; D Maxwell
Journal:  J Obstet Gynaecol       Date:  2010-01       Impact factor: 1.246

2.  Operating on placental support: the ex utero intrapartum treatment procedure.

Authors:  G B Mychaliska; J F Bealer; J L Graf; M A Rosen; N S Adzick; M R Harrison
Journal:  J Pediatr Surg       Date:  1997-02       Impact factor: 2.545

Review 3.  Ex utero intrapartum treatment (EXIT) for upper airway obstruction.

Authors:  Colin R Butler; Elizabeth F Maughan; Pranav Pandya; Richard Hewitt
Journal:  Curr Opin Otolaryngol Head Neck Surg       Date:  2017-04       Impact factor: 2.064

4.  Intrapartum airway management for giant fetal neck masses: the EXIT (ex utero intrapartum treatment) procedure.

Authors:  K W Liechty; T M Crombleholme; A W Flake; M A Morgan; C D Kurth; A M Hubbard; N S Adzick
Journal:  Am J Obstet Gynecol       Date:  1997-10       Impact factor: 8.661

5.  Short-term maternal outcomes that are associated with the EXIT procedure, as compared with cesarean delivery.

Authors:  Melinda M Scully Noah; Mary E Norton; Per Sandberg; Tania Esakoff; Jody Farrell; Craig T Albanese
Journal:  Am J Obstet Gynecol       Date:  2002-04       Impact factor: 8.661

6.  The EXIT procedure: experience and outcome in 31 cases.

Authors:  Sarah Bouchard; Mark P Johnson; Alan W Flake; Lori J Howell; Laura B Myers; N Scott Adzick; Timothy M Crombleholme
Journal:  J Pediatr Surg       Date:  2002-03       Impact factor: 2.545

Review 7.  The EXIT procedure: principles, pitfalls, and progress.

Authors:  Ahmad Marwan; Timothy M Crombleholme
Journal:  Semin Pediatr Surg       Date:  2006-05       Impact factor: 2.754

8.  The ex utero intrapartum treatment procedure: Looking back at the EXIT.

Authors:  Shinjiro Hirose; Diana L Farmer; Hanmin Lee; Kerilyn K Nobuhara; Michael R Harrison
Journal:  J Pediatr Surg       Date:  2004-03       Impact factor: 2.545

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.